CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Enzolytics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Enzolytics Inc
120 W Pomona Ave
Phone: (626) 538-4779p:626 538-4779 MONROVIA, CA  91016  United States Ticker: ENZCENZC
This company ceased filing statements with the SEC on 11/8/2011.
Business Summary
Enzolytics, Inc. is a drug development biotechnology company. The Company is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The Company is focused on developing monoclonal antibody therapy and treating infectious diseases. It has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested anti-HIV therapeutics. The Company has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The Company has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The Company is testing these antibodies to prepare them for use as therapies against these diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201312/31/2011YesYes---

Industries
SIC Code Description
7990 Miscellaneous amusement and recreation services
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer HarryZhabilov 6/16/2017 6/16/2017
President JeffGates 6/27/2012 6/27/2012
Chief Financial Officer MichaelWade 68 9/16/2008 9/16/2008
Executive Vice President, Treasurer, Secretary, Director James W.Zimbler 45 9/16/2008 9/16/2008

Subsidiaries
Business Name Address City State/Province Country
Immunotech Laboratories Inc 120 W Pomona Ave MONROVIA CA United States

Business Names
Business Name
BioClonetics Immunotherapeutics, Inc.
Bottle Brands
ECPO
8 additional Business Names available in full report.

General Information
Number of Employees: 2 (As of 5/13/2011)
Outstanding Shares: 2,970,801,733 (As of 6/30/2023)
Shareholders: 140
Stock Exchange: OTC
Federal Tax Id: 113460949
Fax Number: (845) 818-3588


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023